The Europe Carrier Screening Market was valued at $656.8 Million in 2023 and projected to reach to $1572.7 Million by 2028, representing a compound annual growth rate of 19.1%. Europe's carrier screening market is positioned for sustained expansion through 2028, driven by heightened awareness of genetic disorders, improved access to diagnostic technologies, and supportive healthcare policies across member states.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Europe's carrier screening market reached $656.8 million in 2023 with a projected CAGR of 19.1%, expanding to $1,572.7 million by 2028, demonstrating strong regional momentum in genetic diagnostics.
Supportive regulatory frameworks across EU member states and advanced healthcare infrastructure drive adoption of carrier screening technologies, with emphasis on preventive medicine and genetic risk assessment.
Germany dominates Europe's carrier screening market with $551.0 million in 2023, reflecting strong healthcare investment, robust diagnostic capabilities, and high awareness of genetic screening benefits.
Increasing awareness of genetic disorders combined with advancing diagnostic technologies and next-generation sequencing capabilities accelerate carrier screening adoption across European healthcare systems.
| Report Metric | Details |
|---|---|
| Base Year | 2023 |
| Fastest Growing Segment | PULMONARY CONDITIONS (Medical Condition) |
| Forecast Period | 2023-2028 |
| Growth Rate | CAGR of 19.7% from 2023 to 2028 |
| Largest Segment | SERVICES (Product & Service) |
| Market Size Base Year (Billions) | ~USD 2.2 (2023) |
| Revenue Forecast (Billions) | ~USD 5.4 (2028) |
| Segments Covered | Product & Service, Type, Medical Condition, Technology, End User, Product & 2021-2028 |
6 segment dimensions are covered across the global market.
| Segment | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| CLINICAL LABORATORIES | 118.6 | 138.6 | 163.4 | 192.8 | 227.7 | 269.4 | 319 | 381.5 | 18.5 |
| FERTILITY CLINICS | 48.2 | 55.4 | 64.4 | 74.8 | 87 | 101.4 | 118.3 | 139.3 | 16.7 |
| HOSPITALS AND MEDICAL CENTERS | 280.9 | 332.6 | 397.3 | 475.1 | 568.3 | 680.8 | 816.2 | 988 | 20 |
| OTHER END USERS | 24.4 | 27.7 | 31.7 | 36.4 | 41.7 | 47.9 | 55 | 63.9 | 15 |
| TOTAL | 472.1 | 554.3 | 656.8 | 779 | 924.7 | 1099.5 | 1308.5 | 1572.7 | 19.1 |
| Segment | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| CLINICAL LABORATORIES | 12.1 | 13.9 | 16 | 18.4 | 21.2 | 24.6 | 28.4 | 33.2 | 15.8 |
| FERTILITY CLINICS | 4.9 | 5.5 | 6.3 | 7.1 | 8.1 | 9.2 | 10.5 | 12.1 | 14 |
| HOSPITALS AND MEDICAL CENTERS | 28.8 | 33.3 | 38.8 | 45.4 | 53 | 62 | 72.7 | 85.9 | 17.2 |
| OTHER END USERS | 2.5 | 2.8 | 3.1 | 3.5 | 3.9 | 4.4 | 4.9 | 5.6 | 12.4 |
| TOTAL | 48.3 | 55.4 | 64.2 | 74.4 | 86.2 | 100.2 | 116.5 | 136.8 | 16.3 |
| Country | 2025 size (native) |
|---|---|
| Germany | USD 551 Million |
| UK | USD 339 Million |
| France | USD 256.1 Million |
| Italy | USD 154.2 Million |
| Spain | USD 135.7 Million |
| Rest Of Europe | USD 136.8 Million |
Europe's carrier screening market was valued at $656.8 million in 2023 and is expected to reach $1,572.7 million by 2028.
Europe's carrier screening market is growing at a compound annual growth rate of 19.1% from 2023 to 2028.
Growth in Europe is driven by increased genetic disorder awareness, advancing diagnostic technologies, supportive regulatory frameworks, and rising adoption of non-invasive prenatal testing.
Europe's advanced healthcare infrastructure and regulatory support are distributed across member states, with strong adoption in countries with established genomic medicine programs.
Europe's 19.1% CAGR aligns closely with the global 19.7% CAGR, demonstrating that Europe is a key contributor to worldwide carrier screening market expansion.
The study involved four major activities in estimating the current size of the Carrier Screening Market. Exhaustive secondary research was done to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of the segments and subsegments.
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.
Extensive primary research was conducted after acquiring knowledge about the global market scenario through secondary research. Primary interviews were conducted from both the demand (Doctors, Surgeons, Gynecologist, genetic consultant) and supply sides (Carrier Screening product/service providers and distributors).
The following is a breakdown of the primary respondents:

Note 1: Others include sales managers, marketing managers, and product managers.
Note 2. Tiers of companies are defined based on their total revenue. As of 2021: Tier 1 = >USD 5 billion, Tier 2 = USD 500 million to USD 5 billion, and Tier 3 = <USD 500 million.
To know about the assumptions considered for the study, download the pdf brochure
Both top-down and bottom-up approaches were used to estimate and validate the total size of the Carrier Screening Market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

To know about the assumptions considered for the study, Request for Free Sample Report

After arriving at the overall market size—using the market size estimation processes—the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the Carrier Screening Market industry.
Carrier screening is a type of genetic testing that is used to determine if a person is a carrier for a specific autosomal recessive disease. Similarly, when it is done before or during pregnancy, it allows to find out the chances of having a child with a genetic disorder. Carrier screening involves testing a sample of blood, saliva, or tissue from the inside of the cheek.
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
Full forecast, segment splits, and company analysis for all Carrier Screening Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report